- Home
- BORR vs CTMX Comparison
BORR vs CTMX Comparison
Compare BORR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- CTMX
- Stock Information
- Founded
- BORR 2016
- CTMX 2008
- Country
- BORR Bermuda
- CTMX United States
- Employees
- BORR N/A
- CTMX N/A
- Industry
- BORR Oil & Gas Production
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- CTMX Health Care
- Exchange
- BORR Nasdaq
- CTMX Nasdaq
- Market Cap
- BORR 481.0M
- CTMX 444.3M
- IPO Year
- BORR 2019
- CTMX 2015
- Fundamental
- Price
- BORR $2.22
- CTMX $2.40
- Analyst Decision
- BORR Buy
- CTMX Strong Buy
- Analyst Count
- BORR 2
- CTMX 2
- Target Price
- BORR $9.00
- CTMX $5.00
- AVG Volume (30 Days)
- BORR 4.4M
- CTMX 1.5M
- Earning Date
- BORR 08-13-2025
- CTMX 08-07-2025
- Dividend Yield
- BORR 6.33%
- CTMX N/A
- EPS Growth
- BORR 10.54
- CTMX 128.27
- EPS
- BORR 0.20
- CTMX 0.49
- Revenue
- BORR $993,200,000.00
- CTMX $147,557,000.00
- Revenue This Year
- BORR $8.35
- CTMX N/A
- Revenue Next Year
- BORR $6.39
- CTMX N/A
- P/E Ratio
- BORR $11.43
- CTMX $4.97
- Revenue Growth
- BORR 19.15
- CTMX 23.81
- 52 Week Low
- BORR $1.55
- CTMX $0.40
- 52 Week High
- BORR $6.93
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- BORR 62.29
- CTMX 51.91
- Support Level
- BORR $1.85
- CTMX $2.32
- Resistance Level
- BORR $1.99
- CTMX $2.47
- Average True Range (ATR)
- BORR 0.10
- CTMX 0.14
- MACD
- BORR 0.02
- CTMX -0.01
- Stochastic Oscillator
- BORR 84.88
- CTMX 17.89
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.